Resveratrol improves delayed r-tPA treatment outcome by reducing MMPs.

Abstract

OBJECTIVES:

Although recombinant tissue plasminogen activator (r-tPA) is currently the most effective treatment for brain ischemic stroke, the 3-h narrow therapeutic windows severely limits its clinical efficacy. We aim to investigate the effect of resveratrol on improving treatment outcomes of delayed r-tPA administration.

MATERIALS & METHODS:

Patients were randomly divided according to their onset-to-treatment time (OTT), as early OTT or delayed OTT. Then, they were either treated with r-tPA + placebo or with r-tPA + resveratrol. Twenty-four hours after the treatment, outcomes were assessed with NIH stroke scale (NIHSS), and plasma levels of MMP-2 and MMP-9 were also examined with ELISA.

RESULTS:

In patients receiving delayed r-tPA treatment, co-administration of resveratrol significantly improves their treatment outcomes compared with those receiving placebo, as indicated by improved NIHSS scores. This improved outcome was be caused by resveratrol-induced reduction in plasma levels of both matrix metalloproteinase (MMP)-2 and MMP-9, as a positive correlation was observed between reductions in both MMPs and patient NIHSS scores.

CONCLUSIONS:

Resveratrol could be potentially administered as an adjuvant with r-tPA treatment, which extends the clinical therapeutic window of r-tPA, therefore improving the outcome of patients receiving late stroke treatment.

• Authors: J Chen, Q Bai, Z Zhao, H Sui, X Xie
• Journal: Acta neurologica Scandinavica (Acta Neurol Scand) Vol. 134 Issue 1 Pg. 54-60 (Jul 2016) ISSN: 1600-0404 [Electronic] Denmark
• PMID: 26455907 (Publication Type: Journal Article, Randomized Controlled Trial)
• Copyright: © 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Chemical References

• Antioxidants
• Fibrinolytic Agents
• Stilbenes
• Tissue Plasminogen Activator
• MMP2 protein, human
• Matrix Metalloproteinase 2
• MMP9 protein, human
• Matrix Metalloproteinase 9
• Resveratrol

Topics

• Aged
• Antioxidants (administration & dosage)
• Female
• Fibrinolytic Agents (administration & dosage)
• Humans
• Male
• Matrix Metalloproteinase 2 (blood)
• Matrix Metalloproteinase 9 (blood)
• Middle Aged
• Resveratrol
• Stilbenes (administration & dosage)
• Stroke (blood, drug therapy)
• Time Factors
• Tissue Plasminogen Activator (administration & dosage)
• Treatment Outcome